INTERCEPT PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 501
- Market Cap
- -
Intercept's Ocaliva Faces Setback as FDA Advisory Committee Recommends Against Full Approval for PBC
The FDA's Gastrointestinal Drugs Advisory Committee (GIDAC) has voted against full approval of Intercept's Ocaliva for primary biliary cholangitis (PBC).
© Copyright 2025. All Rights Reserved by MedPath